Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers

New England Journal of Medicine

Volumn 344, Issue 3, 2001, Pages 175-181

  Bensinger, William I ^a,b   Martin, Paul J ^a,b   Storer, Barry ^a,b   Clift, Reginald ^a   Forman, Steven J ^c   Negrin, Robert ^d   Kashyap, Ashwin ^c   Flowers, Mary E D ^a,b   Lilleby, Kathy ^a   Chauncey, Thomas R ^a,b   Storb, Rainer ^a,b   Appelbaum, Frederick R ^a,b   Rowley, Scott ^e   Heimfeld, Shelly ^e   Blume, Karl ^d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC SYSTEM TUMOR; HLA MATCHING; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SURVIVAL RATE;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CAUSE OF DEATH; CHILD; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FILGRASTIM; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; INCIDENCE; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0035905908     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200101183440303     Document Type: Article

References (30)

1. Factors that influence collection and engraftment of autolognus peripheral-blood stem cells
2. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor
3. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts
4. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor)
5. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation
6. Allogeneic blood stem cell transplantation in advanced hematologic cancers
7. Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors
8. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease
9. Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors: A case-control study
10. Allogeneic peripheral blood stem cell transplantation for haematologic malignancies - An analysis of kinetics of engraftment and GVHD risk
11. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies
12. Allogeneic peripheral blood progenitor cell transplantation: Analysis of short-term engraftment and acute GVHD incidence in 33 cases
13. Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: Graft-versus-host disease and transplant-related mortality
14. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation
15. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies
16. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: First results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation
17. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the Société Française de Greffe de Moelle
18. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: A randomised trial
19. Three to six year follow-up of normal donors who received recombinant human granulocyte colony stimulating factor
20. Acute graft-versus-host disease: Analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate
21. 1994 Consensus conference on acute GVHD grading
22. Chronic graft-versus-host disease and other late complications of bone marrow transplantation
23. Nonparametric estimation from incomplete observations
24. Haemopoietic reconstitution by donor-derived myelodysplastic progenitor cells after haemopoietic stem cell transplantation
25. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease
26. Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation
27. CD14+ cells in granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood mononuclear cells induce secretion of interleukin-6 and G-CSF by marrow stroma
28. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells
29. The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow